This publication reports on newly diagnosed cancers registered in England in addition to cancer deaths registered in England during 2020. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document.

In 2020, approximately 58 men and 43 women per 100,000 population died from lung cancer in England and Wales. During the provided time interval, there has been a noticeable decrease in the mortality of lung cancer among men, while the rate among women has remained at similar levels since the year 2000.

This statistic shows the number of deaths from cervical cancer in England from 2014 to 2021. In 2021, the number of deaths from cervical cancer reached 702, an increase from 681 deaths in 2020.

Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.

This statistic shows the rate of registrations of newly diagnosed cases of lung cancer per 100,000 population in England in 2020, by region and gender. With a rate of 100.8 newly diagnosed males with lung cancer and 90.8 females per 100,000 population in 2020, the region most affected by lung cancer was the North East.

One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

This release summarises the diagnoses in 2019 registered by NDRS covering all registerable neoplasms (all cancers, all in situ tumours, some benign tumours and all tumours that have uncertain or unknown behaviours)

Update 2 March 2023: Following the merger of NHS Digital and NHS England on 1st February 2023 we are reviewing the future presentation of the NHS Outcomes Framework indicators. As part of this review, the annual publication which was due to be released in March 2023 has been delayed. Further announcements about this dataset will be made on this page in due course. Directly standardised mortality rate from cancer for people aged under 75, per 100,000 population. To ensure that the NHS is held to account for doing all that it can to prevent deaths from cancer in people under 75. Some different patterns have been observed in the 2020 mortality data which are likely to have been impacted by the coronavirus (COVID-19) pandemic. Statistics from this period should also be interpreted with care. Legacy unique identifier: P01733

This statistic shows the rate of registrations of newly diagnosed cases of ovarian cancer per 100,000 population in England in 2020, by region. With a rate of 22.4 newly diagnosed females with ovarian cancer per 100,000 population in 2020, the regions most affected by ovarian cancer was North West.

Legacy unique identifier: P01733

This statistic shows the rate of registrations of newly diagnosed cases of prostate cancer per 100,000 population in England in 2020, by region. With a rate of 160.2 newly diagnosed males with prostate cancer per 100,000 population in 2020, the region most affected by prostate cancer was South East.

According to Cognitive Market Research, the global Cancer Cachexia market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of XX from 2024 to 2031.

• The global Cancer Cachexia market will expand significantly by XX% CAGR between 2024 and 2031. • North America held a market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Asia Pacific held the major market of more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Latin America's market will have more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. • According to Cognitive Market Research, Progestogens is the dominant therapeutic segment for the cancer cachexia market. • According to Cognitive Market Research, Appetite Stimulators is the dominant mechanism action segment for the cancer cachexia market.

MARKET DYNAMICS:

Key Drivers

Increase in the incidence of cancer fuels the demand for Cancer Cachexia Treatment

One of the key drivers behind the significant growth in cancer cachexia treatment is the rising prevalence of cancer globally. As cancer rates continue to increase, particularly in aging populations, the demand for effective cachexia management strategies grows accordingly. For instance. For instance, The International Agency Research on Cancer- Globocan 2020 report states that out of 19,292,789 new cancer cases recognized worldwide in 2020, 9,958,133 deaths were attributed to cancer. There will be 50,550,287 cancer cases worldwide in the next five years, according to forecasts. By 2040, 28,887,940 new cases of cancer are expected worldwide. (Source:https://www.uicc.org/news/globocan-2020-global-cancer-data) Furthermore, according to GLOBOCAN 2020, 495,773 pancreatic, 604,100 esophageal, 1,414,259 prostate, and 1,148,515 colon cancer cases were identified worldwide in 2020, accounting for 2,206771 new cancer cases. Cachexia is very common in patients with the cancer types listed above, so over the next few years, there will be a growing need for cancer cachexia treatment. Thus, the increase in cancer incidence surges demand for advanced therapeutics drugs, which drives the growth of cancer cachexia market.

Key Restrain

The stringent government policies and high cost associated with the treatment hampers Cancer Cachexia market growth

The stringent government policies and the high costs associated with the treatment presents a significant barrier to the growth of the market. Since terminally sick cancer patients are more likely to experience cancer cachexia, yet medications used to treat this disorder typically have to closely follow the same guidelines as other cancer medications. Many countries have lengthy approval processes for pharmaceuticals, particularly those connected to cancer, due to strict regulatory standards. The amount of time needed for countries to approve cancer medications following their current national regulatory criteria varies greatly. For instance, The CHMP in Europe has 210 days to provide its opinion. This is followed by a period of decision-making phase which may extend upto three months. As a result, patients typically acquire access to promising medications (such as those for cancer cachexia) at varying times. This significantly limits the majority of large corporations' capacity marketing ability. Many individuals miss out on potentially necessary treatment that might be utilized to improve their quality of life because cancer cachexia drugs are given to terminally ill patients due to delayed authorization in various nations (Source:https://extranet.who.int/prequal/sites/default/files/document_files/article_58_guidelines.pdf) In addition, the expense of treating cancer patients with cachexia is significantly higher than that of t...

Directly age standardised mortality rate from breast cancer for females in the respective time period per 100,000 registered female patients. March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published for 2016-2018 only; all data is based on the most recent methodology. For the historic time series of this indicator please refer to the zip files in the June 2018 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---june-2018 Please note, neither version of the file contains data for 2015-2017; changes in the data processing meant the 2015 data was not comparable to the 2016 and 2017 data processed under the new method. 2) Data are run against CCGs which were in existence at the time of processing. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the June 2018 publication referenced above. Legacy unique identifier: P01819

In 2021, 172.9 females per 100,000 population were registered in England as newly diagnosed with breast cancer. This was an overall increase in comparison to the last few years' rate of registration, and a steep rise from the drop in the rate of registration reported in 2020. This statistic shows the rate of newly diagnosed female cases of breast cancer per 100,000 population in England from 1995 to 2021.

In the years 2016 to 2020, over 99 percent of patients diagnosed with melanoma of the skin in England aged between 15 and 44 years of age would survive for at least one year, while patients this age had a five-year survival rate of nearly 97 percent. The survival rates for melanoma of the skin did generally fall if the patient was older when diagnosed.

In 2021, approximately 666 males per 100,000 and 557 females per 100,000 in England were newly diagnosed with cancer, excluding non-melanoma skin cancer. Overall, the diagnosis rate for males showed a slight decreasing trend over the years, while the rate for females remained relatively stable with minor changes. This statistic shows the rate of newly diagnosed cases of cancer per 100,000 population in England from 2018 to 2021, by gender.

Snapshot img

Glioblastoma Multiforme Treatment Market Size 2024-2028

The glioblastoma multiforme treatment market size is forecast to increase by USD 1.36 billion at a CAGR of 8.2% between 2023 and 2028.

The glioblastoma multiforme (GBM) treatment market is experiencing significant growth due to the rising incidence of this aggressive brain cancer and increasing research and development activities In the healthcare sector. According to the American Brain Tumor Association's Cancer Observatory, GBM accounts for approximately 15% of all primary brain tumors and is the most common malignant brain tumor in adults. Current treatment options include surgery, targeted therapy, and chemotherapy. Surgery remains the primary treatment modality for GBM, with various options such as awake craniotomy and awake craniotomy with intraoperative monitoring. This includes various strategies such as checkpoint inhibitors, monoclonal antibodies, and gene therapy. However, these procedures come with adverse effects such as cognitive impairment and motor deficits. Targeted therapies, such as temozolomide, are used in conjunction with surgery and chemotherapy to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the timely availability of these treatments to patients. Despite advancements in treatment options, the high mortality rate associated with GBM necessitates continued research and development efforts to improve patient outcomes and quality of life.

What will be the Size of the Glioblastoma Multiforme Treatment Market During the Forecast Period?

Request Free Sample

Glioblastoma multiforme (GBM), a malignant tumor of the central nervous system (CNS), is a significant health concern worldwide. According to the Global Cancer Observatory, CNS cancers accounted for approximately 2.3% of all cancer diagnoses and 2.5% of cancer deaths in 2020. This article provides an overview of the current treatment landscape for GBM, focusing on surgical, radiation, chemotherapy, targeted therapy, immunotherapy, and emerging novel therapies. Surgery is the primary treatment modality for GBM, with the primary goal being to remove as much of the tumor as possible while minimizing damage to healthy brain tissue. Ambulatory surgical centers and hospitals offer various surgical procedures, including craniotomy and awake craniotomy. Following surgery, patients typically undergo radiation therapy to target any remaining cancer cells. External beam radiation therapy (EBRT) is the most common approach, delivering high-energy radiation to the tumor site. Chemotherapy is often used in combination with radiation therapy to enhance the therapeutic effect.
Moreover, temozolomide, a chemotherapeutic agent, is the most widely used drug for GBM treatment. Corticosteroids, such as dexamethasone, are also frequently administered to reduce swelling and improve symptoms. Targeted therapies, such as bevacizumab, are designed to specifically target the molecular mechanisms of GBM. These therapies inhibit the growth and spread of cancer cells by blocking the action of specific proteins. Moreover, combination Therapies: Combination therapies, which involve the use of multiple treatment modalities, are increasingly being explored to improve treatment outcomes for GBM. For example, the combination of temozolomide and radiation therapy has been shown to improve survival rates compared to monotherapy. Immunotherapy: Immunotherapy, which harnesses the power of the immune system to fight cancer, is an emerging treatment approach for GBM. Personalized Medicine: The heterogeneity of GBM necessitates personalized treatment approaches.
Thus, drug classes and treatment procedures are being tailored to individual patients based on their unique tumor characteristics, such as genetic mutations and protein expression profiles. The treatment market for GBM is continually evolving, with a focus on developing novel therapies and combination strategies to improve patient outcomes. The pharmaceutical supply chain plays a crucial role in ensuring the availability and accessibility of these treatments. As the understanding of GBM biology deepens, so too will the range and effectiveness of treatment options.

How is this Glioblastoma Multiforme Treatment Industry segmented and which is the largest segment?

The glioblastoma multiforme treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals
  Clinics
  Ambulatory surgical centers


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By End-user Insights

The hospitals segment is estimated to witness significant growth during the forecast period.

Cancer Registry Software Market size was valued at USD 71.35 Million in 2023 and is projected to reach USD 156.71 Million by 2031, growing at a CAGR of 11.4% from 2024 to 2031.

Key Market Drivers

• Rising Global Cancer Incidence: The rising global prevalence of cancer is a major driver of the cancer registry software market. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that the worldwide cancer burden will reach 28.4 million cases in 2040, up 47% from 2020. To efficiently track and manage cancer data, sophisticated registry systems are required given the expanding cancer burden.